Bluebird Bio, Inc. (BLUE)
BLUE Stock Price Chart
Key Info
| Market Cap | 3.12B |
| Revenue (ttm) | 250.02M |
| Net Income (ttm) | -642.17M |
| Shares Out | 66.25M |
| EPS (ttm) | -10.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $46.98 |
| Previous Close | $46.19 |
| Change ($) | 0.79 |
| Change (%) | 1.71% |
| Day's Open | 46.08 |
| Day's Range | 45.90 - 47.49 |
| Day's Volume | 577,191 |
| 52-Week Range | 40.39 - 98.04 |
BLUE Stock News
It's a little-known company with lots going against it, but bluebird bio, Inc (NASDAQ:BLUE) has attracted investments from seven of the investing gurus followed by GuruFocus (and yes, the comp...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data prese...
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal sec...
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advi...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen ...
Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.
A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatm...
Bluebird Bio announced a delay for a gene therapy in treating sickle cell disease, leading BLUE stock to tumble early Thursday. Now, the company expects to ask for approval in late 2022.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta...
Bluebird (BLUE) delivered earnings and revenue surprises of 4.23% and -25.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent o...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On Oct. 19, I reviewed three of the 10 companies a Jeffries health care analyst thinks are most likely to be acquired by members of Big Pharma. Now let's look at numbers four through six on th...
Shares of bluebird bio Inc (NASDAQ: BLUE) are undervalued when weighed against the company's fundamentals, according to a Mizuho Securities analyst. The Bluebird Bio Analyst: Difei Yang initi...
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday,...
bluebird bio Should Be On Your Radar With Multiple Catalysts Expected This Year And 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111...
The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BLUE stock popped. T...
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtag...
bluebird bio hasn't performed well in the stock market of late. Do the biotech's recent woes make this a good opportunity for investors to buy its shares?
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio to present new data from clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy at the 46th EBMT Annual Meeting.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.
Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year.
Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc.
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Both of these biotech companies recently released encouraging data from clinical trials.
bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.
Patients in its clinical trial continue to be nearly free of the disease's most serious symptoms.
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
As of late, it has definitely been a great time to be an investor in bluebird bio.
Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.
Shares of Bluebird Bio Inc. BLUE, +4.80% fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400 million worth of common stock.
About BLUE
bluebird bio, a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaborat... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2013 |
| Employees 1,171 | |
| Stock Exchange NASDAQ | Ticker Symbol BLUE |
Financial Performance
In 2019, Bluebird Bio's revenue was $44.67 million, a decrease of -18.15% compared to the previous year's $54.58 million. Losses were -$789.61 million, 42.1% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Bluebird Bio is 80.95, which is an increase of 72.31% from the latest price.